Protagonist Therapeutics Inc share price logo

Protagonist Therapeutics Inc Share Price

NASDAQ: PTGX

Mid Cap

$102.17

-1.58

(-1.52%)

as on

Protagonist Therapeutics Inc Stock Performance

as on April 9, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $101.61
    $105.24
    downward going graph

    0.55%

    Downside

    3.00%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $39.60
    $107.84
    downward going graph

    61.24%

    Downside

    5.55%

    Upside

    downward going graph

Protagonist Therapeutics Inc share price movements today

Previous Close
$103.75
Open
$104.28
Volume
568.8K
Day's Low - High
$101.61 - $105.24
52 Week Low - High
$39.60 - $107.84

Protagonist Therapeutics Inc Historical Returns

1 Month Return
+ 12.66 %
3 Month Return
+ 29.36 %
1 Year Return
+ 148.98 %
3 Year Return
+ 461.72 %
5 Year Return
+ 288.58 %

Protagonist Therapeutics Inc Stock Fundamentals & Key Indicators

Check Protagonist Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$6.6B

EPS (TTM)

2.7738

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

3.51%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-156.8M

Revenue (TTM)

46.0M

Profit Margin

-282.83%

Return On Equity TTM

-20.18%

Protagonist Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Protagonist Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Protagonist Therapeutics Inc image
Protagonist Therapeutics Inc
BUY$6.6B288.58%NA-282.83%
Insmed Incorporated image
Insmed Incorporated
BUY$35.2B404.42%-16.34-210.54%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$43.8B124.22%141.788.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$110.3B105.37%28.3732.94%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$80.7B59.6%18.4131.41%

Stock Returns calculator for Protagonist Therapeutics Inc Stock including INR - Dollar returns

The Protagonist Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Protagonist Therapeutics Inc investment value today

Current value as on today

₹2,62,489

Returns

₹1,62,489

(+162.49%)

Returns from Protagonist Therapeutics Inc Stock

₹1,45,188 (+145.19%)

Dollar Impact

₹17,301 (+17.3%)

Analyst Recommendation on Protagonist Therapeutics Inc Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Protagonist Therapeutics Inc. Average target price of $112.42

Protagonist Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Protagonist Therapeutics Inc.

What analysts predicted

9.12%UPSIDE

Target Price

$112.42

Current Price

$102.17

Analyzed by

12 Analysts

Target

$112.42

Protagonist Therapeutics Inc target price $112.42, a slight upside of 9.12% compared to current price of $102.17. According to 12 analysts rating.

Protagonist Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Protagonist Therapeutics Inc Stock has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-30% versus previous 30 day period

Protagonist Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
60
254
4
4
170
28
5
4
7
Gross Profit
0
60
254
4
4
170
28
5
4
7
Operating Income
-38
23
206
-38
-41
126
-19
-42
-46
-50
EBITDA
-37
23
206
-37
-40
127
-19
-41
-38
-43
Interest Expense
-
2
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
1
0
0
Income Before Tax
-34
27
210
-31
-33
133
-11
-34
-39
-43
Income Tax Expense
0
-4
3
0
0
1
-
0
-
0
Net Income
-34
27
207
-30
-33
131
-11
-34
-39
-44
Net Profit Margin
0.00%
45.56%
81.32%
-734.73%
-710.37%
77.17%
-41.15%
-626.96%
-834.87%
-596.80%

Protagonist Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
20
30
0
28
27
26
60
434
46
Gross Profit
0
20
30
0
28
27
26
60
434
44
Operating Income
-32
-37
-42
-80
-64
-125
-131
-93
252
-158
EBITDA
-32
-37
-41
-77
-63
-123
-128
-90
253
-128
Interest Expense
-
-
-
0
0
2
3
-
-
-
Depreciation
-
0
0
2
2
2
3
3
2
1
Income Before Tax
-37
-36
-39
-77
-64
-125
-127
-78
279
-129
Income Tax Expense
4
0
0
0
1
-2
-3
-14
4
0
Net Income
-37
-36
-38
-77
-66
-125
-123
-78
275
-130
Net Profit Margin
0.00%
-184.20%
-125.87%
-33414.29%
-231.07%
-458.94%
-464.29%
-131.59%
63.34%
-282.83%

Protagonist Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
27
207
-30
-33
131
-11
-34
-39
85
Operating Cash Flow
16
-27
268
-27
-29
125
-28
-1
-36
Investing Cash Flow
-61
6
-88
-208
-8
-94
54
-58
48
Financing Cash Flow
0
7
2
12
4
11
2
5
2
Change in Cash
-43
-14
183
-224
-33
42
28
-54
14

Protagonist Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-36
-38
-77
-66
-125
-127
-78
275
-130
Operating Cash Flow
3
-49
-41
-72
-107
-108
-70
184
57
Investing Cash Flow
15
2
-53
-90
-15
91
-39
-299
-49
Financing Cash Flow
65
24
46
247
129
18
170
25
22
Change in Cash
85
-23
-49
84
6
2
60
-89
31

Global Institutional Holdings in Protagonist Therapeutics Inc

Funds
Holdings
Jefferies Financial Group Inc
1.32%
T. Rowe Price Associates, Inc.
1.91%
Perceptive Advisors LLC
1.61%
Marshall Wace Asset Management Ltd
1.7%
Vanguard Group Inc
8.48%
See all

Protagonist Therapeutics Inc News & Key Events

  • img

    Today's Timeline - 13 October

    Mon, 07:35 PM

    -

    Johnson & Johnson reportedly in talks to acquire Protagonist Therapeutics, enhancing their collaboration on immunology treatments.

Insights on Protagonist Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, PTGX stock has moved up by 29.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Insmed Incorporated has given 868.7% return, outperforming this stock by 407.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Insmed Incorporated has given 150.9% return, outperforming this stock by 1.9%

About Protagonist Therapeutics Inc

protagonist therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform which is utilized to discover and develop novel peptide-based drugs to address significant unmet medical needs. its primary focus is on developing potential first-in-class oral targeted therapy-based peptide drugs that work by blocking biological pathways that are currently targeted by marketed injectable antibody drugs. protagonist's initial lead peptide product candidates, ptg-100 and ptg-200, are based on this approach, and the company believes these candidates have the potential to transform the existing treatment paradigm for inflammatory bowel disease (ibd), consisting primarily of ulcerative colitis and crohn's disease. ptg-100, a potential first-in-class oral peptide alpha-4-beta-7 integrin antagonist, is currently in a global phase 2b clinical trial for treatment of moderate-to-severe ulcerative colitis. ptg-200, a first-in-class oral interleukin-23 receptor antagonist
OrganisationProtagonist Therapeutics Inc
Headquarters7707 Gateway Boulevard, Newark, CA, United States, 94560
IndustryHealth Technology
CEODr. Dinesh V. Patel Ph.D.
E-voting on sharesClick here to vote

Key Management of Protagonist Therapeutics Inc

Name

Title

Dr. Arturo M. Molina FACP, M.D., M.S.

Chief Medical Officer

Mr. Carter J. King

Executive Vice President of Business Development

Ms. Abha Bommireddi

Executive VP & Chief of Staff

Dr. Dinesh V. Patel Ph.D.

CEO, President, Secretary & Director

Mr. Asif Ali

Executive VP & CFO

Dr. Newman Yeilding M.D.

Executive VP, Chief Scientific Officer

Mr. Matthew M. Gosling J.D.

Executive VP and Chief Legal & Business Officer

Ms. Carena Spivey

Executive VP & Chief Human Resources Officer

Dr. Ashok Bhandari Ph.D.

EVP & Chief Discovery Officer

Dr. Samuel R. Saks M.D.

Clinical Development Advisor

FAQs

What is Protagonist Therapeutics Inc share price today?

Protagonist Therapeutics Inc share price today is $102.17 as on at the close of the market. Protagonist Therapeutics Inc share today touched a day high of $105.24 and a low of $101.61.

What is the 52 week high and 52 week low for Protagonist Therapeutics Inc share?

Protagonist Therapeutics Inc share touched a 52 week high of $107.84 on and a 52 week low of $39.6 on . Protagonist Therapeutics Inc stock price today i.e. is closed at $102.17,which is 5.26% down from its 52 week high and 158.01% up from its 52 week low.

What is Protagonist Therapeutics Inc's market capitalisation today?

Protagonist Therapeutics Inc market capitalisation is $0.01T as on .

How to invest in Protagonist Therapeutics Inc Stock (PTGX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Protagonist Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Protagonist Therapeutics Inc Shares that will get you 0.0147 shares as per Protagonist Therapeutics Inc share price of $102.17 per share as on April 9, 2026 at 1:29 am IST.

What is the minimum amount required to buy Protagonist Therapeutics Inc Stock (PTGX) from India?

Indian investors can start investing in Protagonist Therapeutics Inc (PTGX) shares with as little as ₹92.336 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹923.36 in Protagonist Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Protagonist Therapeutics Inc share’s latest price of $102.17 as on April 9, 2026 at 1:29 am IST, you will get 0.0979 shares of Protagonist Therapeutics Inc. Learn more about fractional shares .

What are the returns that Protagonist Therapeutics Inc has given to Indian investors in the last 5 years?

Protagonist Therapeutics Inc stock has given 288.58% share price returns and 24.79% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?